These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

418 related items for PubMed ID: 12651911

  • 1. Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms.
    Jia L, Kim J, Shen H, Clark PE, Tilley WD, Coetzee GA.
    Mol Cancer Res; 2003 Mar; 1(5):385-92. PubMed ID: 12651911
    [Abstract] [Full Text] [Related]

  • 2. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
    Gong J, Zhu J, Goodman OB, Pestell RG, Schlegel PN, Nanus DM, Shen R.
    Oncogene; 2006 Mar 30; 25(14):2011-21. PubMed ID: 16434977
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The role of protein kinase A pathway and cAMP responsive element-binding protein in androgen receptor-mediated transcription at the prostate-specific antigen locus.
    Kim J, Jia L, Stallcup MR, Coetzee GA.
    J Mol Endocrinol; 2005 Feb 30; 34(1):107-18. PubMed ID: 15691881
    [Abstract] [Full Text] [Related]

  • 5. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M.
    Cancer Res; 2004 Oct 01; 64(19):7156-68. PubMed ID: 15466214
    [Abstract] [Full Text] [Related]

  • 6. Synergistic activation of the androgen receptor by bombesin and low-dose androgen.
    Dai J, Shen R, Sumitomo M, Stahl R, Navarro D, Gershengorn MC, Nanus DM.
    Clin Cancer Res; 2002 Jul 01; 8(7):2399-405. PubMed ID: 12114445
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
    Latham JP, Searle PF, Mautner V, James ND.
    Cancer Res; 2000 Jan 15; 60(2):334-41. PubMed ID: 10667585
    [Abstract] [Full Text] [Related]

  • 9. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
    Zhu ML, Partin JV, Bruckheimer EM, Strup SE, Kyprianou N.
    Prostate; 2008 Feb 15; 68(3):287-95. PubMed ID: 18163430
    [Abstract] [Full Text] [Related]

  • 10. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.
    Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H.
    Cancer Res; 1994 Oct 15; 54(20):5474-8. PubMed ID: 7522959
    [Abstract] [Full Text] [Related]

  • 11. An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines.
    Paliouras M, Diamandis EP.
    Biol Chem; 2008 Jun 15; 389(6):773-80. PubMed ID: 18627304
    [Abstract] [Full Text] [Related]

  • 12. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
    Sadar MD, Gleave ME.
    Cancer Res; 2000 Oct 15; 60(20):5825-31. PubMed ID: 11059779
    [Abstract] [Full Text] [Related]

  • 13. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor.
    Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, Culig Z.
    Cancer Res; 1998 Oct 15; 58(20):4640-5. PubMed ID: 9788616
    [Abstract] [Full Text] [Related]

  • 14. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression.
    Cheng H, Snoek R, Ghaidi F, Cox ME, Rennie PS.
    Cancer Res; 2006 Nov 01; 66(21):10613-20. PubMed ID: 17079486
    [Abstract] [Full Text] [Related]

  • 15. Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells.
    Fujii Y, Kawakami S, Okada Y, Kageyama Y, Kihara K.
    Am J Physiol Endocrinol Metab; 2004 Jun 01; 286(6):E927-31. PubMed ID: 14761877
    [Abstract] [Full Text] [Related]

  • 16. Partial agonist/antagonist properties of androstenedione and 4-androsten-3beta,17beta-diol.
    Chen F, Knecht K, Leu C, Rutledge SJ, Scafonas A, Gambone C, Vogel R, Zhang H, Kasparcova V, Bai C, Harada S, Schmidt A, Reszka A, Freedman L.
    J Steroid Biochem Mol Biol; 2004 Aug 01; 91(4-5):247-57. PubMed ID: 15336702
    [Abstract] [Full Text] [Related]

  • 17. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
    Lazier CB, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS.
    Prostate; 2004 Feb 01; 58(2):130-44. PubMed ID: 14716738
    [Abstract] [Full Text] [Related]

  • 18. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
    Arnold JT, Le H, McFann KK, Blackman MR.
    Am J Physiol Endocrinol Metab; 2005 Mar 01; 288(3):E573-84. PubMed ID: 15536203
    [Abstract] [Full Text] [Related]

  • 19. The chromatin remodeling factor SRCAP modulates expression of prostate specific antigen and cellular proliferation in prostate cancer cells.
    Slupianek A, Yerrum S, Safadi FF, Monroy MA.
    J Cell Physiol; 2010 Aug 01; 224(2):369-75. PubMed ID: 20432434
    [Abstract] [Full Text] [Related]

  • 20. Androgen receptor-mediated repression of novel target genes.
    Prescott J, Jariwala U, Jia L, Cogan JP, Barski A, Pregizer S, Shen HC, Arasheben A, Neilson JJ, Frenkel B, Coetzee GA.
    Prostate; 2007 Sep 15; 67(13):1371-83. PubMed ID: 17624924
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.